Clinical Trial Update: A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of D3S-001 as a monotherapy or combination therapy in advanced solid tumors with KRAS p.G12C mutation is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• D3S-001

Snippet

Sponsor: D3 Bio (Wuxi) Co., Ltd | Conditions: KRAS P.G12C | Phase 1, Phase 2 | Status: RECRUITING